| Literature DB >> 25310104 |
Elgar Susanne Quabius1, Jochen Haag2, André Kühnel1, Hannes Henry1, Anna Sophie Hoffmann3, Tibor Görögh1, Jürgen Hedderich4, Matthias Evert5, Achim G Beule6, Steffen Maune7, Rainald Knecht8, Attila Óvári9, Martin Durisin10, Florian Hoppe11, Silke Tribius12, Christoph Röcken2, Petra Ambrosch1, Markus Hoffmann1.
Abstract
The increased knowledge regarding HPV-infections in head and neck squamous cell carcinoma (HNSCC) has unexpectedly contributed to several uncertainties related to i) prevalence diversities depending on tumour site and geographical origin of the patients, ii) proportion of HPV-driven tumours among HPV-DNA-positive cases, and iii) identification of patients with HPV-attributed survival benefit. To investigate this heterogeneity, we analysed 307 HNSCC cases (tonsillar, n=135; non-tonsillar, n=172) from eight health care centers mostly from Northern Germany and determined HPV-DNA/mRNA and p16INK4A-status and combined results with the patient outcome. Overall HPV-DNA prevalence rate was 23.5% (72/307); attributed to: 43.7% (59/135) and 7.6% (13/172) tonsillar and non-tonsillar cases, respectively. Among these, 96.6% tonsillar and 38.5% non-tonsillar SCC were HPV-mRNA-positive. Although the study cohort was composed of patients from regions of rather close proximity, prevalence rates showed diversities of up to 40% in HNSCC subsite analysis with the lowest prevalence for tonsillar SCC in metropolitan areas (22.2%) vs. 50.9% in rural areas. Survival analysis identified p16INK4A alone as strongest predictor, followed by HPV-DNA-status alone or in combination with p16INK4A. This survival benefit was shown for tonsillar and non-tonsillar cases. Smoking significantly correlated with HPV-status, however, it does not influence survival when stratified for HPV. In conclusion, the data emphasize the urge for further data on HPV-infection in HNSCC to, e.g. clarify to what extent survival benefits of p16INK4A-positive patients are truly attributed to HPV-infections.Entities:
Mesh:
Year: 2014 PMID: 25310104 DOI: 10.3892/ijo.2014.2697
Source DB: PubMed Journal: Int J Oncol ISSN: 1019-6439 Impact factor: 5.650